Tectonic Therapeutic, Inc. in brief
Tectonic Therapeutic, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2015. Its last known market value was $66 M (January 2024); there is no current figure. It employs about 60 people and Alise Reicin is its chief executive. Its shares trade under the symbol TECX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Tectonic Therapeutic, Inc.
Avrobio is a Clinical Stage Personalized Gene Therapy company. It is having 85 employees as on 2019. The headquarters is in USA.
Tectonic Therapeutic, Inc. timeline
- 2015
- 🏁· approximateFounded
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as AVROBIO, Inc.Final prospectus filed with the SEC on 21 June 2018; shares registered for exchange trading on 18 June 2018.
- 2024
- ✎Renamed Tectonic Therapeutic, Inc.Formerly AVROBIO, Inc..
Events of Tectonic Therapeutic, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,286 (Jan 2020) · #2,631 (Jan 2021) · #4,469 (Jan 2022) · #5,042 (Dec 2022) · #4,524 (Jul 2023) · #3,928 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -29.5%
- Liabilities / assets
- 3.7%
- Net debt
- $-78M
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-84M | $-74M | — |
| Dec 2024 | — | — | $-58M | $-58M | — |
| Dec 2023 | — | — | $-45M | $-43M | — |
| Dec 2022 | — | — | $-105M | $-106M | — |
| Dec 2021 | — | — | $-119M | $-119M | — |
| Dec 2020 | — | — | $-120M | $-120M | — |
| Dec 2019 | — | — | $-76M | $-73M | — |
| Dec 2018 | — | — | $-46M | $-46M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-60M | $0M | $-60M | $-4.05 | $0.00 |
| Dec 2024 | $-59M | $0M | $-59M | $-6.83 | $0.00 |
| Dec 2023 | $-41M | $0M | $-41M | $-33.76 | — |
| Dec 2022 | $-97M | $0M | $-97M | $-2.42 | — |
| Dec 2021 | $-98M | $2M | $-100M | $-2.78 | — |
| Dec 2020 | $-99M | $1M | $-100M | $-3.31 | — |
| Dec 2019 | $-68M | $2M | $-69M | $-2.66 | — |
| Dec 2018 | $-38M | $2M | $-39M | $-3.62 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportAcquisition or disposal completed
- Sep 29, 20268-KCurrent reportOther events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 10, 20268-KCurrent reportShareholder vote · Other events
- May 7, 20268-KCurrent reportResults of operations
- May 7, 202610-QQuarterly report · period to Mar 2026
- Apr 24, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Feb 26, 20268-KCurrent reportResults of operations
- Feb 26, 202610-KAnnual report · period to Dec 2025
Official filings of Tectonic Therapeutic, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-84 M
- Net income
- $-74 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $261 M
- Total liabilities
- $10 M
- Total equity
- $251 M
As of December-2025
Top 100 institutional investors in Tectonic Therapeutic, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 2,932,368 | +101,990 (+3.60%) | 14.70% | $68 M | Nov 10, 2026 |
| 2 | TCG Crossover Management, LLC | 1,204,891 | 0 (0.00%) | 6.04% | $28 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 860,736 | -1,856 (-0.22%) | 4.31% | $20 M | Nov 13, 2026 |
| 4 | Baker Bros. Advisors LP | 607,788 | 0 (0.00%) | 3.05% | $14 M | Nov 16, 2026 |
| 5 | 5AM Venture Management, LLC | 606,660 | 0 (0.00%) | 3.04% | $14 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 512,412 | +23,607 (+4.83%) | 2.57% | $12 M | Nov 13, 2026 |
| 7 | First Light Asset Management, LLC | 495,950 | -304,776 (-38.06%) | 2.49% | $12 M | Nov 16, 2026 |
| 8 | Aberdeen Group plc | 484,887 | -656,937 (-57.53%) | 2.43% | $11 M | Nov 10, 2026 |
| 9 | Marshall Wace, LLP | 446,511 | +274,410 (+159.45%) | 2.24% | $10 M | Nov 13, 2026 |
| 10 | Braidwell LP | 371,102 | -225,798 (-37.83%) | 1.86% | $9 M | Nov 16, 2026 |
| 11 | Vestal Point Capital, LP | 360,000 | -65,000 (-15.29%) | 1.80% | $8 M | Nov 16, 2026 |
| 12 | Ikarian Capital, LLC | 306,338 | +100,501 (+48.83%) | 1.54% | $7 M | Nov 16, 2026 |
| 13 | Kennedy Capital Management LLC | 302,542 | +20,340 (+7.21%) | 1.52% | $7 M | Nov 13, 2026 |
| 14 | Geode Capital Management, LLC | 283,119 | +12,658 (+4.68%) | 1.42% | $7 M | Nov 6, 2026 |
| 15 | State Street Corp | 220,780 | +872 (+0.40%) | 1.11% | $5 M | Nov 12, 2026 |
| 16 | Raymond James Financial Inc | 197,393 | +124,719 (+171.61%) | 0.99% | $5 M | Nov 12, 2026 |
| 17 | Citadel Advisors LLC | 193,039 | +102,646 (+113.56%) | 0.97% | $4 M | Nov 16, 2026 |
| 18 | Sphera Funds Management LTD. | 187,438 | New | 0.94% | $4 M | Nov 16, 2026 |
| 19 | Goldman Sachs Group Inc | 184,429 | +110,505 (+149.48%) | 0.92% | $4 M | Nov 16, 2026 |
| 20 | D. E. Shaw & Co., Inc. | 182,528 | -4,022 (-2.16%) | 0.92% | $4 M | Nov 16, 2026 |
| 21 | Qube Research & Technologies Ltd | 178,427 | New | 0.89% | $4 M | Nov 13, 2026 |
| 22 | ExodusPoint Capital Management, LP | 167,083 | +131,844 (+374.14%) | 0.84% | $4 M | Nov 16, 2026 |
| 23 | Orbimed Advisors LLC | 166,102 | -60,498 (-26.70%) | 0.83% | $4 M | Nov 16, 2026 |
| 24 | Ameriprise Financial Inc | 143,027 | +579 (+0.41%) | 0.72% | $3 M | Nov 16, 2026 |
| 25 | Squarepoint Ops LLC | 141,065 | -3,963 (-2.73%) | 0.71% | $3 M | Nov 9, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bollard Group LLC | 140,953 | -162,000 (-53.47%) | 0.71% | $3 M | Nov 13, 2026 |
| 27 | Vanguard Portfolio Management LLC | 138,738 | +44,324 (+46.95%) | 0.70% | $3 M | Nov 13, 2026 |
| 28 | HRT Financial LP | 134,756 | +90,216 (+202.55%) | 0.68% | $3 M | Nov 13, 2026 |
| 29 | Millennium Management LLC | 126,963 | -38,562 (-23.30%) | 0.64% | $3 M | Nov 16, 2026 |
| 30 | Hudson Bay Capital Management LP | 125,000 | New | 0.63% | $3 M | Nov 13, 2026 |
| 31 | Wells Fargo & Company/mn | 115,508 | -1,920 (-1.64%) | 0.58% | $3 M | Nov 16, 2026 |
| 32 | Northern Trust Corp | 115,119 | +1,215 (+1.07%) | 0.58% | $3 M | Nov 16, 2026 |
| 33 | Woodline Partners LP | 100,000 | 0 (0.00%) | 0.50% | $2 M | Nov 16, 2026 |
| 34 | Balyasny Asset Management L.P. | 91,096 | New | 0.46% | $2 M | Nov 16, 2026 |
| 35 | Boothbay Fund Management, LLC | 90,278 | +29,507 (+48.55%) | 0.45% | $2 M | Nov 16, 2026 |
| 36 | Vanguard Fiduciary Trust Co | 79,900 | +11,506 (+16.82%) | 0.40% | $2 M | Nov 13, 2026 |
| 37 | Morgan Stanley | 75,142 | +9,769 (+14.94%) | 0.38% | $2 M | Nov 13, 2026 |
| 38 | Sectoral Asset Management Inc | 72,592 | +1,583 (+2.23%) | 0.36% | $2 M | Nov 13, 2026 |
| 39 | Jane Street Group, LLC | 67,247 | +1,426 (+2.17%) | 0.34% | $2 M | Nov 12, 2026 |
| 40 | Connor, Clark & Lunn Investment Management Ltd. | 64,687 | -253 (-0.39%) | 0.32% | $2 M | Nov 10, 2026 |
| 41 | Jump Financial, LLC | 60,534 | +17,134 (+39.48%) | 0.30% | $1 M | Nov 13, 2026 |
| 42 | Trexquant Investment LP | 57,870 | +20,879 (+56.44%) | 0.29% | $1 M | Nov 16, 2026 |
| 43 | Jpmorgan Chase & Co | 53,760 | -1,604 (-2.90%) | 0.27% | $1 M | Nov 12, 2026 |
| 44 | Dimensional Fund Advisors LP | 53,705 | +43,262 (+414.27%) | 0.27% | $1 M | Nov 4, 2026 |
| 45 | ADAR1 Capital Management, LLC | 49,501 | +35,000 (+241.36%) | 0.25% | $1 M | Nov 16, 2026 |
| 46 | Price T Rowe Associates Inc /MD/ | 48,001 | 0 (0.00%) | 0.24% | $1 M | Nov 16, 2026 |
| 47 | Susquehanna International Group, LLP | 43,617 | New | 0.22% | $1 M | Nov 16, 2026 |
| 48 | XTX Topco Ltd | 41,963 | New | 0.21% | $1 M | Nov 16, 2026 |
| 49 | Y-Intercept (Hong Kong) Ltd | 41,463 | New | 0.21% | $1 M | Oct 16, 2026 |
| 50 | Wellington Management Group LLP | 37,149 | +5,717 (+18.19%) | 0.19% | $1 M | Nov 16, 2026 |
| 51 | Aldebaran Capital, LLC | 36,220 | -577 (-1.57%) | 0.18% | $1 M | Nov 13, 2026 |
| 52 | Charles Schwab Investment Management Inc | 31,765 | +1,327 (+4.36%) | 0.16% | $1 M | Nov 16, 2026 |
| 53 | Monimus Capital Management, LP | 28,143 | 0 (0.00%) | 0.14% | $1 M | Nov 16, 2026 |
| 54 | Simplex Trading, LLC | 27,520 | +27,081 (+6168.79%) | 0.14% | $1 M | Nov 4, 2026 |
| 55 | Tetragon Partners GP Ltd | 26,798 | -19,718 (-42.39%) | 0.13% | $1 M | Nov 16, 2026 |
| 56 | Alps Advisors Inc | 25,886 | +6,739 (+35.20%) | 0.13% | $1 M | Nov 3, 2026 |
| 57 | Bank of New York Mellon Corp | 25,636 | +389 (+1.54%) | 0.13% | $1 M | Nov 5, 2026 |
| 58 | American Century Companies Inc | 23,143 | +4,142 (+21.80%) | 0.12% | $1 M | Nov 12, 2026 |
| 59 | Russell Investments Group, Ltd. | 21,978 | +16,411 (+294.79%) | 0.11% | $1 M | Nov 6, 2026 |
| 60 | Engineers Gate Manager LP | 19,336 | New | 0.10% | $0 M | Nov 16, 2026 |
| 61 | Fisher Asset Management, LLC | 19,122 | 0 (0.00%) | 0.10% | $0 M | Nov 6, 2026 |
| 62 | SEI Investments Co | 17,029 | 0 (0.00%) | 0.09% | $0 M | Nov 10, 2026 |
| 63 | Clearstead Advisors, LLC | 16,630 | 0 (0.00%) | 0.08% | $0 M | Nov 6, 2026 |
| 64 | UBS Group AG | 15,786 | +731 (+4.86%) | 0.08% | $0 M | Nov 10, 2026 |
| 65 | Nuveen, LLC | 14,960 | +1,446 (+10.70%) | 0.07% | $0 M | Nov 10, 2026 |
| 66 | Barclays PLC | 14,731 | +5,603 (+61.38%) | 0.07% | $0 M | Nov 6, 2026 |
| 67 | Quantinno Capital Management LP | 13,705 | New | 0.07% | $0 M | Nov 13, 2026 |
| 68 | Rhumbline Advisers | 13,199 | -574 (-4.17%) | 0.07% | $0 M | Nov 10, 2026 |
| 69 | Bank Of America Corp /de/ | 12,452 | +1,409 (+12.76%) | 0.06% | $0 M | Nov 16, 2026 |
| 70 | Strs Ohio | 12,200 | New | 0.06% | $0 M | Oct 30, 2026 |
| 71 | Seven Fleet Capital Management LP | 12,000 | New | 0.06% | $0 M | Nov 16, 2026 |
| 72 | Gsa Capital Partners LLP | 11,304 | +3,029 (+36.60%) | 0.06% | $0 M | Nov 16, 2026 |
| 73 | China Universal Asset Management Co., Ltd. | 10,767 | +5,264 (+95.66%) | 0.05% | $0 M | Oct 28, 2026 |
| 74 | Virtus Investment Advisers, LLC | 10,480 | -326 (-3.02%) | 0.05% | $0 M | Nov 12, 2026 |
| 75 | Deutsche Bank AG\ | 8,732 | -1,307 (-13.02%) | 0.04% | $0 M | Nov 6, 2026 |
| 76 | AlphaCentric Advisors LLC | 7,161 | +213 (+3.07%) | 0.04% | $0 M | Nov 3, 2026 |
| 77 | MetLife Investment Management, LLC | 6,724 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 78 | Nisa Investment Advisors, LLC | 5,400 | 0 (0.00%) | 0.03% | $0 M | Oct 20, 2026 |
| 79 | Vanguard Global Advisers, LLC | 5,051 | -3,714 (-42.37%) | 0.03% | $0 M | Nov 13, 2026 |
| 80 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 4,962 | +268 (+5.71%) | 0.02% | $0 M | Nov 16, 2026 |
| 81 | New York State Common Retirement Fund | 4,600 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 82 | Los Angeles Capital Management LLC | 3,600 | New | 0.02% | $0 M | Nov 12, 2026 |
| 83 | BNP Paribas Financial Markets | 3,005 | -2,141 (-41.61%) | 0.02% | $0 M | Nov 12, 2026 |
| 84 | Citigroup Inc | 2,846 | -2,702 (-48.70%) | 0.01% | $0 M | Nov 4, 2026 |
| 85 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,841 | +2,459 (+643.72%) | 0.01% | $0 M | Nov 16, 2026 |
| 86 | Police & Firemen's Retirement System of New Jersey | 2,638 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 87 | Royal Bank Of Canada | 1,510 | +1,199 (+385.53%) | 0.01% | $0 M | Nov 16, 2026 |
| 88 | Ameritas Investment Partners, Inc. | 1,122 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 89 | US Bancorp \de\ | 1,070 | -10 (-0.93%) | 0.01% | $0 M | Nov 5, 2026 |
| 90 | Legal & General Group Plc | 1,000 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 91 | Mirae Asset Global Investments Co., Ltd. | 999 | +155 (+18.36%) | 0.01% | $0 M | Oct 29, 2026 |
| 92 | Chung Wu Investment Group, LLC | 800 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 93 | HighMark Wealth Management LLC | 587 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 94 | GF Fund Management Co. LTD. | 433 | +33 (+8.25%) | 0.00% | $0 M | Oct 26, 2026 |
| 95 | Tower Research Capital LLC (TRC) | 418 | -243 (-36.76%) | 0.00% | $0 M | Nov 16, 2026 |
| 96 | State of Wyoming | 399 | -202 (-33.61%) | 0.00% | $0 M | Oct 28, 2026 |
| 97 | Rockefeller Capital Management L.P. | 370 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 98 | GAMMA Investing LLC | 314 | +24 (+8.28%) | 0.00% | $0 M | Oct 8, 2026 |
| 99 | Federation des caisses Desjardins du Quebec | 250 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 100 | Sterling Capital Management LLC | 237 | +61 (+34.66%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Tectonic Therapeutic, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 770,940 | $27 M | 3.9% | 1.9% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 720,235 | $22 M | 3.6% | 0.02% | +2.9% | May 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 370,884 | $13 M | 1.9% | 1.8% | no change | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 405,389 | $13 M | 2.0% | 0.24% | −8.5% | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 364,413 | $13 M | 1.8% | <0.01% | +4.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 268,951 | $9 M | 1.3% | 0.01% | −0.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 248,743 | $8 M | 1.2% | 0.03% | +1.2% | May 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 196,522 | $6 M | 0.99% | 0.03% | +2.9% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 111,919 | $4 M | 0.56% | <0.01% | +0.3% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Growth FundColumbia Funds Series Trust I | 121,484 | $4 M | 0.61% | 0.10% | −2.4% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 120,995 | $3 M | 0.61% | 0.15% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 112,159 | $3 M | 0.56% | <0.01% | +3.1% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 78,065 | $3 M | 0.39% | 0.02% | +2.0% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 66,553 | $2 M | 0.33% | 0.03% | −12% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 56,310 | $2 M | 0.28% | 0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 50,753 | $2 M | 0.25% | <0.01% | −2.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 34,417 | $1 M | 0.17% | 0.08% | +24% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 30,632 | $1 M | 0.15% | <0.01% | −75% | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 28,408 | $1 M | 0.14% | 0.14% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 25,625 | $1 M | 0.13% | <0.01% | +5.5% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 19,539 | $1 M | 0.10% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 19,034 | $1 M | 0.10% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 19,826 | $1 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 19,353 | $1 M | 0.10% | 0.37% | +16% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 16,713 | $1 M | 0.08% | 0.02% | +47% | May 31, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 13,971 | $0 M | 0.07% | 0.04% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 14,801 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 11,802 | $0 M | 0.06% | 0.02% | +4.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 12,644 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 13,514 | $0 M | 0.07% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,609 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 10,971 | $0 M | 0.05% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 8,806 | $0 M | 0.04% | 0.02% | −5.8% | Jun 30, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Small Company Growth FundColumbia Management Investment Advisers, LLC | 8,302 | $0 M | 0.04% | 0.11% | −8.7% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 7,800 | $0 M | 0.04% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 7,996 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,494 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 6,993 | $0 M | 0.04% | 0.02% | +5.4% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 5,979 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,470 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 5,318 | $0 M | 0.03% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 5,529 | $0 M | 0.03% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 5,330 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,323 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 4,059 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 4,416 | $0 M | 0.02% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 4,882 | $0 M | 0.02% | <0.01% | +2.1% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,900 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 4,711 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 3,507 | $0 M | 0.02% | 0.10% | — | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,381 | $0 M | 0.02% | 0.01% | −20% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 3,967 | $0 M | 0.02% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 3,118 | $0 M | 0.02% | 0.04% | −5.3% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,060 | $0 M | 0.02% | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 3,060 | $0 M | 0.02% | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 3,665 | $0 M | 0.02% | <0.01% | +3.5% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 2,888 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 2,930 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,288 | $0 M | 0.01% | 0.04% | +17% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 2,166 | $0 M | 0.01% | 0.02% | −14% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,161 | $0 M | 0.01% | 0.01% | +7.2% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 2,081 | $0 M | 0.01% | <0.01% | −73% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,061 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 2,052 | $0 M | 0.01% | 0.02% | −5.0% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 1,842 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 1,702 | $0 M | <0.01% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 1,809 | $0 M | <0.01% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 1,794 | $0 M | <0.01% | 0.02% | new | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,536 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,473 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,775 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,430 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,426 | $0 M | <0.01% | 0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,392 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 1,289 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 1,276 | $0 M | <0.01% | <0.01% | +14078% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 1,551 | $0 M | <0.01% | 0.01% | +5.4% | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,551 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 1,512 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,300 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,122 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 1,127 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,002 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,090 | $0 M | <0.01% | <0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,040 | $0 M | <0.01% | <0.01% | −18% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 832 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 975 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 964 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 756 | $0 M | <0.01% | 0.01% | −72% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 735 | $0 M | <0.01% | 0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 720 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 707 | $0 M | <0.01% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 659 | $0 M | <0.01% | 0.02% | −9.0% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 536 | $0 M | <0.01% | 0.01% | −72% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 641 | $0 M | <0.01% | <0.01% | +85% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 517 | $0 M | <0.01% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 465 | $0 M | <0.01% | <0.01% | −39% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 523 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 420 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 393 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Tectonic Therapeutic, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alise ReicinChief Executive Officer, Director | Option exercise | +10,000 | $2.380 | $24 K | 319,078 | Form 4 |
| filed | Peter McNamaraChief Scientific Officer | Sell10b5-1 plan | -536 | $23.04 | $12 K | 54,305 | Form 4 |
| filed | Alise ReicinChief Executive Officer, Director | Shares withheld for tax | -1,545 | $23.67 | $37 K | 309,078 | Form 4 |
| filed | Daniel LochnerChief Financial Officer | Shares withheld for tax | -520 | $23.67 | $12 K | 58,024 | Form 4 |
| filed | Marc SchwabishChief Business Officer | Shares withheld for tax | -411 | $23.67 | $10 K | 44,903 | Form 4 |
| filed | Peter McNamaraChief Scientific Officer | Shares withheld for tax10b5-1 plan | -444 | $23.67 | $11 K | 54,841 | Form 4 |
| filed | Marcella K. RuddyChief Medical Officer | Shares withheld for tax | -525 | $23.67 | $12 K | 67,157 | Form 4 |
| filed | Peter McNamaraChief Scientific Officer | Option exercise10b5-1 plan | +43 | $14.71 | $633 | 55,328 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Tectonic Therapeutic, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1.89 reverse split ; 4.312-for-1 split
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2025 | $0.000 |
Trading halts
- 2025-10-29 20:00 UTC, code T3, resumed 20:30 UTC
- 2025-01-28 18:57 UTC, code LUDP, resumed 19:02 UTC
- 2025-01-28 18:43 UTC, code LUDP, resumed 18:48 UTC
- 2025-01-28 18:25 UTC, code LUDP, resumed 18:35 UTC
- 2025-01-28 18:12 UTC, code LUDP, resumed 18:22 UTC
Fails to deliver
- : 1,049 shares at $20.34
- : 4,969 shares at $20.07
- : 1 shares at $24.12
- : 306 shares at $30.48
- : 19,728 shares at $37.63
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Tectonic Therapeutic, Inc. scorecard#
Passes 2 of the 9 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.05 vs -6.83Diluted EPS -4.05 in fiscal 2025 against -6.83 the year before (report's currency).
- ✓Net income higher than five years earlier-$74 M-$74 M in fiscal 2025 against -$120 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$74 MNet income -$74 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-37.8%-37.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities26.6×Current ratio 26.61 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 2
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year115.8%Diluted shares up 115.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Tectonic Therapeutic, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Research and development | 63+53.5%— | 41+11.9%— | 37r48−48.8%— | 72−13.1%— | 83−4.7%— | 87+58.7%— | 55+56.6%— | 35+131%— | 15—— | |
| General and administrative | 21+23.4%— | 17+117%— | 7.7r24−76.9%— | 33−6.9%— | 36+8.3%— | 33+58.3%— | 21+86.9%— | 11+249%— | 3.2—— | |
| Operating expenses | 84+44.9%— | 58+29.9%— | 45r72−57.7%— | 105−11.3%— | 119−1.2%— | 120+58.6%— | 76+63.9%— | 46+152%— | 18—— | |
| Total costs and expenses | 3.7+2.7%— | 3.6+1.1%— | 3.6r2.1+20.4%— | 3.0—— | — | — | — | — | — | |
| Operating income | −84—— | −58—— | −45r10—— | −105—— | −119—— | −120—— | −76—— | −46—— | −18—— | |
| Interest and finance income | 11+165%— | 4.3+633%— | 0.6—— | — | — | 0.7−75.5%— | 2.9+70.0%— | 1.7+2928%— | 0.1—— | |
| Interest expense and finance costs | 0.1−41.1%— | 0.1−29.6%— | 0.2r1.9−91.6%— | 1.8+791%— | 0.2—— | — | — | — | — | |
| Other non-operating income (expense) | 11+33582%— | 0.0−98.2%— | 1.8r2.3—— | −0.5—— | −0.3−155%— | 0.5−81.9%— | 2.8—— | −0.1—— | −0.3—— | |
| Income before tax | −73—— | −58—— | — | — | — | — | — | — | — | |
| Income tax | 1.2—— | 0—— | 0r0.4—— | 0—— | — | — | — | — | — | |
| Net income including minority interests | −74—— | −58—— | −43r12—— | −106—— | −119—— | −120—— | −73—— | −46—— | −19—— | |
| Net income attributable to shareholders | −74—— | −58—— | −43r12—— | −106—— | −119—— | −120—— | −73—— | −46—— | −19—— | |
| Earnings per share, basic | -4.05—— | -6.83—— | -33.76r0.27—— | -2.42—— | -2.78—— | -3.31—— | -2.66—— | -3.62—— | -8.38—— | |
| Earnings per share, diluted | -4.05—— | -6.83—— | -33.76r0.27—— | -2.42—— | -2.78—— | -3.31—— | -2.66—— | -3.62—— | -8.38—— | |
| Shares, weighted average (basic) | 18+116%— | 8.5+569%— | 1.3r44−97.1%— | 44r0.0+101965%— | 0.0—— | — | — | — | — | |
| Shares, weighted average (diluted) | 18+116%— | 8.5+569%— | 1.3r45−97.1%— | 44r0.0+101965%— | 0.0r43−99.9%— | 36+32.0%— | 27r27+104%— | 13+501%— | 2.2—— | |
| Dividends per share | 0.00—— | 0.00—— | — | — | — | — | — | — | — | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 254+79.7%97.2% | 141+391%92.4% | 29r98−68.9%73.0% | 93−51.2%89.0% | 190−27.0%93.0% | 260+38.8%95.7% | 187+48.1%93.3% | 126+2018%94.6% | 6.0—84.9% | |
| Other current assets | 3.0−47.1%1.1% | 5.6+886%3.7% | 0.6−43.5%1.4% | 1.0−40.6%1.0% | 1.7+527%0.8% | 0.3r0.3−21.2%0.1% | 0.3r0.6−56.7%0.2% | 0.8+1225%0.6% | 0.1—0.9% | |
| Current assets | 257+75.2%98.6% | 147+376%96.0% | 31r100−69.1%78.4% | 100−49.8%96.2% | 199−25.5%97.7% | 267+36.6%98.5% | 196+50.5%97.6% | 130+1961%97.4% | 6.3—89.8% | |
| Property, plant and equipment | 1.2−44.9%0.5% | 2.2−31.1%1.4% | 3.1r0+7.9%7.9% | 2.9−29.9%2.8% | 4.1+34.7%2.0% | 3.1−17.1%1.1% | 3.7+40.3%1.8% | 2.6+655%2.0% | 0.3—5.0% | |
| Right-of-use (leased) assets | 0.9−60.9%0.3% | 2.2−16.3%1.5% | 2.7r0.4+153%6.8% | 1.1—1.0% | 0—0.0% | — | — | — | — | |
| Total assets | 261+70.7%100% | 153+288%100% | 39r101−62.1%100% | 104−49.0%100% | 204−24.8%100% | 271+35.3%100% | 201+50.2%100% | 133+1801%100% | 7.0—100% | |
| Accounts payable | 1.1+12.0%0.4% | 1.0+139%0.6% | 0.4r0.0+6.5%1.0% | 0.4−89.0%0.4% | 3.5+30.0%1.7% | 2.7−32.1%1.0% | 3.9+41.8%2.0% | 2.8+428%2.1% | 0.5—7.5% | |
| Current liabilities | 9.7−16.7%3.7% | 12−71.6%7.6% | 41r6.4+212%104% | 13−32.3%12.6% | 19+16.7%9.5% | 17+18.5%6.1% | 14+32.2%7.0% | 11+304%7.9% | 2.6—37.4% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.1−92.0%0.1% | 1.6r0+774%4.2% | 0.2—0.2% | 0—0.0% | — | — | — | — | |
| Total liabilities | 9.7−20.0%3.7% | 12−72.1%7.9% | 43r6.4+51.9%110% | 29−16.8%27.5% | 34+103%16.9% | 17+16.5%6.2% | 15+28.4%7.2% | 11+209%8.5% | 3.7—52.1% | |
| Retained earnings | −223—−85.3% | −149—−97.2% | −91r−477—−230% | −489—−471% | −384—−188% | −264—−97.5% | −145—−72.2% | −72—−53.7% | −23—−334% | |
| Shareholders' equity | 251+78.5%96.3% | 141—92.1% | −85r95—−215% | −46r75−127%−43.9% | 169−33.4%83.1% | 254+36.7%93.8% | 186+52.2%92.8% | 122—91.5% | −23—−329% | |
| Total liabilities and equity | 261+70.7%100% | 153+288%100% | 39r101−62.1%100% | 104−49.0%100% | 204−24.8%100% | 271+35.3%100% | 201+50.2%100% | 133+1801%100% | 7.0—100% | |
| Shares outstanding | 19+26.1%— | 15+955%— | 1.4r45−96.8%— | 44+0.6%— | 44r420.0%— | 44r42+38.0%— | 32r32+32.9%— | 24+933%— | 2.3—— | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 1.4−16.4%— | 1.6+11.3%— | 1.5r0.6+2.6%— | 1.4+2.9%— | 1.4+15.9%— | 1.2+42.0%— | 0.9+124%— | 0.4+744%— | 0.0—— | |
| Share-based compensation | 10+201%— | 3.5+211%— | 1.1r6.9−90.3%— | 12−38.0%— | 19+18.9%— | 16+130%— | 6.8+210%— | 2.2+1141%— | 0.2—— | |
| Cash from operating activities | −60—— | −59—— | −41r−63—— | −97—— | −98—— | −99—— | −68—— | −38—— | −16—— | |
| Capital expenditure | −0.2—— | −0.2—— | −0.3r−0.0—— | −0.3—— | −2.5—— | −1.2—— | −1.6—— | −1.8—— | −0.4—— | |
| Cash from investing activities | −0.1—— | −0.2—— | −0.3r85—— | −0.3—— | −2.5—— | −1.2—— | −1.6—— | −1.8—— | −0.4—— | |
| Debt issued | — | — | — | 0−100%— | 15—— | — | — | — | — | |
| Shares issued | — | — | 0.1−57.8%— | 0.2—— | — | — | 129+24.5%— | 104—— | — | |
| Cash from financing activities | 173+1.0%— | 172+409%— | 34r−16+12781%— | 0.3−99.1%— | 30−82.4%— | 173+32.8%— | 130−18.9%— | 160+823%— | 17—— | |
| Exchange-rate effect on cash | −0.1—— | −0.0−150%— | 0.0—— | — | — | — | — | — | — | |
| Change in cash | 113+0.5%— | 112—— | −7.2r5.9—— | −97—— | −70−197%— | 73+19.6%— | 61−49.7%— | 121+19835%— | 0.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 73+29.1%— | 17+3.0%— | 18+5.0%— | 21+60.1%— | 16*+78.5%— | 17+18.2%— | 17+143%— | 13+20.5%— | 9.2*+27.3%— | 14—— | 7.1—— | 11r0.7—— | 7.2r4.4*—— | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | 0*—— | 9.9—— | — | — | |
| General and administrative | 24+17.7%— | 6.0+21.2%— | 6.2+19.9%— | 6.4+22.2%— | 5.2*+7.0%— | 5.0−6.7%— | 5.1+18.4%— | 5.3+145%— | 4.8*+122%— | 5.3—— | 4.3—— | 2.2r7.3—— | 2.2r5.2*—— | |
| Operating expenses | 96+26.1%— | 23+7.2%— | 24+8.4%— | 27+49.2%— | 22*+53.8%— | 22+11.5%— | 22+95.5%— | 18+41.1%— | 14*+49.3%— | 20—— | 11—— | 13r7.9—— | 9.4r9.6*—— | |
| Total costs and expenses | 4.1—— | 1.0+8.0%— | 1.0+11.1%— | 1.1+17.9%— | 0.9*—— | 0.9—— | 0.9+7.5%— | 0.9+177%— | — | — | 0.9—— | 0.3—— | 1.6r0.4*—— | |
| Operating income | −96—— | −23—— | −24—— | −27—— | −22*—— | −22—— | −22—— | −18—— | −14*—— | −20—— | −11—— | −13r−7.9—— | −9.4r−9.7*—— | |
| Interest and finance income | 8.9−15.2%— | 2.1−27.0%— | 2.0−40.4%— | 2.2−10.8%— | 2.6*+47.8%— | 2.9+48.6%— | 3.4+966%— | 2.4+855%— | 1.7*+1205%— | 2.0—— | 0.3—— | 0.3—— | 0.1*—— | |
| Interest expense and finance costs | 0.0−58.9%— | 0.0−71.4%— | 0.0−64.7%— | 0.0−60.0%— | 0.0*−45.5%— | 0.0−44.0%— | 0.0−39.3%— | 0.0−35.5%— | 0.0*−35.3%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | 8.7−14.4%— | 2.1−26.1%— | 2.0−39.5%— | 2.1−13.9%— | 2.5*+57.2%— | 2.9+48.7%— | 3.3—— | 2.4—— | 1.6*+7.5%— | 1.9—— | −1.3—— | −2.3r1.1—— | 1.5r1.3*—— | |
| Income before tax | — | −21—— | −22—— | — | −19*—— | −19—— | −19—— | — | −12*—— | −18—— | −13—— | — | — | |
| Income tax | — | 0—— | 0.1−92.1%— | — | 0.3*—— | 0—— | 1.0—— | — | 0*—— | 0—— | 0—— | — | 0r0.4*—— | |
| Net income including minority interests | −88—— | −21*—— | −22*—— | −25—— | −19*—— | −19*—— | −20*—— | −16—— | −12*—— | −18*—— | −13r−21*—— | −15r−6.8—— | −7.9r−8.8*—— | |
| Net income attributable to shareholders | −88—— | −21—— | −22—— | −25—— | −19*—— | −19—— | −20—— | −16—— | −12*—— | −18—— | −13—— | −15r−6.8—— | −7.9r−8.8*—— | |
| Earnings per share, basic | — | -1.08—— | -1.18—— | -1.34—— | — | -1.02—— | -1.07—— | -0.93—— | — | -1.20—— | -4.34—— | -10.97r-0.15—— | — | |
| Earnings per share, diluted | — | -1.08—— | -1.18—— | -1.34—— | — | -1.02—— | -1.07—— | -0.93—— | — | -1.20—— | -4.34—— | -10.97r-0.15—— | — | |
| Shares, weighted average (basic) | 20+5.3%— | 20+5.3%— | 19+1.5%— | 19+9.4%— | — | 19+27.0%— | 19+540%— | 17+1137%— | — | 15—— | 2.9—— | 1.4r45—— | — | |
| Shares, weighted average (diluted) | 20+5.3%— | 20+5.3%— | 19+1.5%— | 19+9.4%— | — | 19+27.0%— | 19+540%— | 17+1137%— | — | 15—— | 2.9—— | 1.4r45—— | — | |
| Dividends per share | — | — | — | — | — | — | — | 0.00—— | — | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 235—96.2% | 235−12.6%96.2% | 227−21.0%95.8% | 237−22.6%96.1% | 254+79.7%97.2% | 268+68.7%96.9% | 287+55.2%97.3% | 306+1533%97.3% | 141+391%92.4% | 159—94.3% | 185—95.5% | 19r90—20.3% | 29r98—73.0% | |
| Other current assets | 3.9—1.6% | 3.9−7.9%1.6% | 4.0+16.2%1.7% | 3.0−11.8%1.2% | 3.0−47.1%1.1% | 4.2+20.4%1.5% | 3.5+53.1%1.2% | 3.4+443%1.1% | 5.6+886%3.7% | 3.5—2.1% | 2.3—1.2% | 0.6—0.7% | 0.6—1.4% | |
| Current assets | 239—97.8% | 239−12.7%97.8% | 231−20.5%97.5% | 240−22.5%97.3% | 257+75.2%98.6% | 273+68.0%98.6% | 291+55.2%98.5% | 310+237%98.4% | 147+376%96.0% | 163—96.4% | 187—96.6% | 92—99.4% | 31r100—78.4% | |
| Property, plant and equipment | 0.8—0.3% | 0.8−43.8%0.3% | 0.9−49.0%0.4% | 1.0−47.0%0.4% | 1.2−44.9%0.5% | 1.4−44.6%0.5% | 1.7−36.2%0.6% | 1.9—0.6% | 2.2−31.1%1.4% | 2.6—1.5% | 2.6—1.4% | — | 3.1r0—7.9% | |
| Right-of-use (leased) assets | 3.2—1.3% | 3.2+386%1.3% | 3.7+206%1.6% | 4.1+138%1.7% | 0.9−60.9%0.3% | 0.7−62.4%0.2% | 1.2−0.6%0.4% | 1.7+1467%0.5% | 2.2−16.3%1.5% | 1.8—1.0% | 1.2—0.6% | 0.1—0.1% | 2.7r0.4—6.8% | |
| Total assets | 244—100% | 244−12.0%100% | 237−19.7%100% | 247−21.7%100% | 261+70.7%100% | 277+64.2%100% | 295+52.3%100% | 315+241%100% | 153+288%100% | 169—100% | 194—100% | 92—100% | 39r101—100% | |
| Accounts payable | 1.6—0.7% | 1.6+9.4%0.7% | 1.7−40.2%0.7% | 2.6−59.2%1.0% | 1.1+12.0%0.4% | 1.5−43.6%0.5% | 2.8−31.4%0.9% | 6.3+2474%2.0% | 1.0+139%0.6% | 2.6—1.6% | 4.1—2.1% | 0.2—0.3% | 0.4r0.0—1.0% | |
| Current liabilities | 12—5.0% | 12+29.1%5.0% | 10−8.7%4.4% | 13−4.1%5.3% | 9.7−16.7%3.7% | 9.4−45.9%3.4% | 11−56.3%3.8% | 14+285%4.3% | 12−71.6%7.6% | 17—10.3% | 26—13.4% | 3.5—3.8% | 41r6.4—104% | |
| Lease liabilities (non-current) | 2.4—1.0% | 2.4—1.0% | 2.8—1.2% | 3.2—1.3% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 0.1−92.0%0.1% | 0.5—0.3% | 0.9—0.5% | — | 1.6r0—4.2% | |
| Total liabilities | 15—6.0% | 15+53.4%6.0% | 13+14.2%5.6% | 16+17.2%6.6% | 9.7−20.0%3.7% | 9.5−48.4%3.4% | 12−58.1%3.9% | 14+293%4.4% | 12−72.1%7.9% | 18—10.9% | 28—14.2% | 3.5—3.8% | 43r6.4—110% | |
| Retained earnings | −292—−120% | −292—−120% | −270—−114% | −248—−101% | −223—−85.3% | −204—−73.5% | −184—−62.5% | −164—−52.2% | −149—−97.2% | −136—−80.7% | −118—−61.1% | −484—−524% | −91r−477—−230% | |
| Shareholders' equity | 229—94.0% | 229−14.3%94.0% | 224−21.1%94.4% | 230−23.5%93.4% | 251+78.5%96.3% | 268+77.9%96.6% | 284+70.6%96.1% | 301—95.6% | 141—92.1% | 150—89.1% | 166—85.8% | −100r89—−108% | −85r95—−215% | |
| Total liabilities and equity | 244—100% | 244−12.0%100% | 237−19.7%100% | 247−21.7%100% | 261+70.7%100% | 277+64.2%100% | 295+52.3%100% | 315+241%100% | 153+288%100% | 169—100% | 194—100% | 92—100% | 39r101—100% | |
| Shares outstanding | 20—— | 20+6.5%— | 19+2.8%— | 19+0.9%— | 19+26.1%— | 19+26.9%— | 19+27.0%— | 19−58.4%— | 15+955%— | 15—— | 15—— | 45—— | 1.4r45—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.2−24.4%— | 0.3*−26.9%— | 0.3*−16.2%— | 0.3−15.6%— | 0.3*−34.4%— | 0.3*−19.3%— | 0.3*+1.2%— | 0.4−4.5%— | 0.5*+36.2%— | 0.4*—— | 0.3r0.7*—— | 0.4r0—— | 0.4r0*—— | |
| Share-based compensation | 14+67.4%— | 4.2*+50.3%— | 4.0*+55.0%— | 3.2+52.4%— | 3.0*+168%— | 2.8+70.7%— | 2.6+542%— | 2.1+555%— | 1.1*+280%— | 1.7—— | 0.4—— | 0.3r0.9—— | 0.3r0.6*—— | |
| Cash from operating activities | −69—— | −15*—— | −21*—— | −18—— | −14*—— | −18*—— | −15*—— | −13—— | −17*—— | −20*—— | −13r−15*—— | −9.3r−7.6—— | −12r−8.0*—— | |
| Capital expenditure | −0.1—— | 0*—— | −0.1*—— | −0.0—— | 0*—— | −0.2*—— | 0*—— | −0.0—— | −0.0*—— | −0.2*—— | — | −0.0r0—— | −0.1r0*—— | |
| Cash from investing activities | −0.1—— | 0*—— | −0.1*−207%— | −0.0—— | 0*—— | −0.2*—— | 0.1*+1275%— | −0.0—— | −0.0*—— | −0.2*—— | 0.0r0*—— | −0.0r0—— | −0.1r0.2*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | 0.0—— | 0*—— | |
| Cash from financing activities | 35−79.8%— | 23*—— | 12*—— | 0.8−99.5%— | −0.1*—— | −0.5*—— | −4.2*−102%— | 178—— | −1.1*−103%— | −6.3*—— | 180r179*—— | −0.7r0.0—— | 34r0.1*—— | |
| Exchange-rate effect on cash | 0.1—— | 0*—— | 0.0*—— | 0.1—— | −0.0*−195%— | −0.0*−253%— | −0.0*−300%— | −0.0—— | 0.0*+131%— | 0.0*—— | 0.0*—— | −0.1—— | 0.0*—— | |
| Change in cash | −34−131%— | 7.6*—— | −9.8*—— | −17−111%— | −15*—— | −18*—— | −19*−111%— | 165—— | −18*−180%— | −26*—— | 166r164*—— | −10r−7.5—— | 22r−7.8*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Tectonic Therapeutic, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Tectonic Therapeutic, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Alise Reicin | $7.4 M | −$4.4 M | $3.1 M | $244 |
| 2024Alise Reicin, Erik Ostrowski | $5.9 M | $16.2 M | $2.1 M | $540 |
| 2023Erik Ostrowski | $1.6 M | $1.9 M | $1.1 M | $191 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Tectonic Therapeutic, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Acquisition or sale completed | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Tectonic Therapeutic, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $135 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist IBiochemists and Biophysicists | 1 | $135 K |
Where: Watertown, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $135 K | 1 |
| FY2025 | 1 | 1 | $124 K | 1 |
| FY2024 | 1 | 1 | $87 K | 1 |
| FY2023 | 1 | 1 | $100 K | 1 |
| FY2022 | 1 | 1 | $65 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Tectonic Therapeutic, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 600 K | · | · | · | · | · | · | · | · | · | · | · | 600 K |
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 600,000 people | Restructuring planSEC 8-K | “Following completion of the ongoing dose escalation safety and PK/PD studies in healthy volunteers, development of TX45 is planned to focus on an area of very high unmet need, Grou…” | Filing | |
| 50% of workforce | Restructuring planSEC 8-K | “The Board also approved a reduction in the Company’s workforce by approximately 50% across different areas and functions in the Company (the “ Workforce Reduction ”).” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 23% of workforce | Restructuring planSEC 8-K | “As part of this plan, the Committee approved a reduction in the Company’s workforce by approximately 23% across different areas and functions in the Company (the “Workforce Reducti…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Tectonic Therapeutic, Inc.🇺🇸 | $66 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Tectonic Therapeutic, Inc.? Verify and update this profile — free
Show Tectonic Therapeutic, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.